Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ZHONGXING LIAO and RADHE MOHAN.
ZHONGXING LIAO
Connection Strength
5.311
RADHE MOHAN
  1. Reply to R. Rengan et al. J Clin Oncol. 2018 07 01; 36(19):2004-2005.
    View in: PubMed
    Score: 0.632
  2. Future of Protons Depends on Precision. J Clin Oncol. 2018 07 01; 36(19):2002.
    View in: PubMed
    Score: 0.632
  3. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
    View in: PubMed
    Score: 0.617
  4. Coronary artery calcium score on standard of care oncologic CT scans for the prediction of adverse cardiovascular events in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy. Front Cardiovasc Med. 2022; 9:1071701.
    View in: PubMed
    Score: 0.217
  5. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
    View in: PubMed
    Score: 0.180
  6. Impact of Intra-Fractional Motion on Dose Distributions in Lung IMRT. J Radiother Pract. 2021 Mar; 20(1):12-16.
    View in: PubMed
    Score: 0.177
  7. Potential for Improvements in Robustness and Optimality of Intensity-Modulated Proton Therapy for Lung Cancer with 4-Dimensional Robust Optimization. Cancers (Basel). 2019 Jan 01; 11(1).
    View in: PubMed
    Score: 0.165
  8. Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):403-410.
    View in: PubMed
    Score: 0.163
  9. Patterns of Local-Regional Failure After Intensity Modulated Radiation Therapy or Passive Scattering Proton Therapy With Concurrent Chemotherapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):123-131.
    View in: PubMed
    Score: 0.161
  10. Clinical and Dosimetric Factors Predicting Grade =2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):919-926.
    View in: PubMed
    Score: 0.157
  11. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737.
    View in: PubMed
    Score: 0.153
  12. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
    View in: PubMed
    Score: 0.135
  13. Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Pract Radiat Oncol. 2015 Mar-Apr; 5(2):e77-86.
    View in: PubMed
    Score: 0.123
  14. Effects of respiratory motion on passively scattered proton therapy versus intensity modulated photon therapy for stage III lung cancer: are proton plans more sensitive to breathing motion? Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):576-82.
    View in: PubMed
    Score: 0.116
  15. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1332-9.
    View in: PubMed
    Score: 0.110
  16. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1010-6.
    View in: PubMed
    Score: 0.106
  17. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1573-9.
    View in: PubMed
    Score: 0.106
  18. Predicting pneumonitis risk: a dosimetric alternative to mean lung dose. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):522-7.
    View in: PubMed
    Score: 0.104
  19. Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):251-7.
    View in: PubMed
    Score: 0.104
  20. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e537-43.
    View in: PubMed
    Score: 0.103
  21. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):332-9.
    View in: PubMed
    Score: 0.101
  22. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81.
    View in: PubMed
    Score: 0.085
  23. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):278-87.
    View in: PubMed
    Score: 0.081
  24. Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer. Int J Part Ther. 2024 Mar; 11:100012.
    View in: PubMed
    Score: 0.060
  25. Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):368-377.
    View in: PubMed
    Score: 0.057
  26. Quantifying the Effect of 4-Dimensional Computed Tomography-Based Deformable Dose Accumulation on Representing Radiation Damage for Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Standard-Fractionated Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Jan 01; 118(1):231-241.
    View in: PubMed
    Score: 0.057
  27. Optimization of mesh generation for geometric accuracy, robustness, and efficiency of biomechanical-model-based deformable image registration. Med Phys. 2023 Jan; 50(1):323-329.
    View in: PubMed
    Score: 0.053
  28. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100391.
    View in: PubMed
    Score: 0.053
  29. Geometric and dosimetric accuracy of deformable image registration between average-intensity images for 4DCT-based adaptive radiotherapy for non-small cell lung cancer. J Appl Clin Med Phys. 2021 Aug; 22(8):156-167.
    View in: PubMed
    Score: 0.049
  30. The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. Adv Radiat Oncol. 2021 Mar-Apr; 6(2):100635.
    View in: PubMed
    Score: 0.047
  31. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. Radiother Oncol. 2019 04; 133:9-15.
    View in: PubMed
    Score: 0.041
  32. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563.
    View in: PubMed
    Score: 0.039
  33. The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. Front Oncol. 2017; 7:201.
    View in: PubMed
    Score: 0.038
  34. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.038
  35. Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using In?Vivo Imaging Biomarkers. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):1013-1020.
    View in: PubMed
    Score: 0.037
  36. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. Sci Rep. 2017 04 03; 7(1):588.
    View in: PubMed
    Score: 0.037
  37. (18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):670-8.
    View in: PubMed
    Score: 0.035
  38. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol. 2015 Mar; 114(3):367-72.
    View in: PubMed
    Score: 0.032
  39. Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort. Acta Oncol. 2014 May; 53(5):590-6.
    View in: PubMed
    Score: 0.029
  40. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447.
    View in: PubMed
    Score: 0.027
  41. Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy? Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e69-76.
    View in: PubMed
    Score: 0.027
  42. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.